دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Universal Definition of Heart Failure, risk prediction in cardiogenic shock, artificial intelligence in cardiac allograft rejection, and the genetics of dilated cardiomyopathy
Filippo Crea
doi : 10.1093/eurheartj/ehab370
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2317–2320
Artificial Intelligence in Global Health
Chayakrit Krittanawong, Scott Kaplin
doi : 10.1093/eurheartj/ehab036
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2321–2322
Getting lost in the fog of the pandemic: insights from the ‘second wave’ of COVID-19
Massimo Mapelli
doi : 10.1093/eurheartj/ehab035
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2323–2325
Imaging in the European Heart Journal: the team of Deputy and Associate Editors Chiara Bucciarelli-Ducci, Jo?o L. Cavalcante, and Nina Ajmone-Marsan
doi : 10.1093/eurheartj/ehab228
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Page 2326
Transseptal left heart catheterization: birth, death, and resurrection
Eugene Braunwald
doi : 10.1093/eurheartj/ehab264
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2327–2328
The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk
Massimo Volpe, Carlo Patrono
doi : 10.1093/eurheartj/ehab268
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2329–2330
The struggle towards a Universal Definition of Heart Failure—how to proceed?
John G F Cleland, Marc A Pfeffer, Andrew L Clark, James L Januzzi, John J V McMurray, Christian Mueller, Pierpaolo Pellicori, Mark Richards, John R Teerlink, Faiez Zannad, Johann Bauersachs
doi : 10.1093/eurheartj/ehab082
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2331–2343
The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction
Uta Ceglarek, Paul Schellong, Maciej Rosolowski, Markus Scholz, Anja Willenberg, Jürgen Kratzsch, Uwe Zeymer, Georg Fuernau, Suzanne de Waha-Thiele, Petra Büttner, Alexander Jobs, Anne Freund, Steffen Desch, Hans-Josef Feistritzer, Berend Isermann, Joachim Thiery, Janine P?ss, Holger Thiele
doi : 10.1093/eurheartj/ehab110
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2344–2352
Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) still reaches excessively high mortality rates. This analysis is aimed to develop a new easily applicable biomarker-based risk score.
Scores for outcome prediction in patients admitted with cardiogenic shock
Kurt Huber
doi : 10.1093/eurheartj/ehab211
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2353–2355
no abstract
An automated computational image analysis pipeline for histological grading of cardiac allograft rejection
Eliot G Peyster, Sara Arabyarmohammadi, Andrew Janowczyk, Sepideh Azarianpour-Esfahani, Miroslav Sekulic, Clarissa Cassol, Luke Blower, Anil Parwani, Priti Lal, Michael D Feldman, Kenneth B Margulies, Anant Madabhushi
doi : 10.1093/eurheartj/ehab241
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2356–2369
Allograft rejection is a serious concern in heart transplant medicine. Though endomyocardial biopsy with histological grading is the diagnostic standard for rejection, poor inter-pathologist agreement creates significant clinical uncertainty. The aim of this investigation is to demonstrate that cellular rejection grades generated via computational histological analysis are on-par with those provided by expert pathologists
Can automatic image analysis replace the pathologist in cardiac allograft rejection diagnosis?
Mitko Veta, Paul J van Diest, Aryan Vink
doi : 10.1093/eurheartj/ehab226
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2370–2372
What can heart failure trialists learn from oncology trialists?
Faiez Zannad, Gad Cotter, Angeles Alonso Garcia, Suzanne George, Beth Davison, Gemma Figtree, Krishna Prasad, Frank Rockhold, Richard L Schilsky, Norman Stockbridge, Bertram Pitt, Javed Butler
doi : 10.1093/eurheartj/ehab236
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2373–2383
Globally, there has been little change in mortality rates from cardiovascular (CV) diseases or cancers over the past two decades (1997–2018). This is especially true for heart failure (HF) where 5-year mortality rates remain as high as 45–55%. In the same timeframe, the proportion of drug revenue, and regulatory drug approvals for cancer drugs, far out paces those for CV drugs. In 2018, while cancer drugs made 27% of Food and Drug Administration drug approvals, only 1% of drug approvals was for a CV drug, and over this entire 20?year span, only four drugs were approved for HF in the USA. Cardiovascular trialists need to reassess the design, execution, and purpose of CV clinical trials. In the area of oncology research, trials are much smaller, follow-up is shorter, and targeted therapies are common. Cardiovascular diseases and cancer are the two most common causes of death globally, and although they differ substantially, this review evaluates whether some elements of oncology research may be applicable in the CV arena. As one of the most underserved CV diseases, the review focuses on aspects of cancer research that may be applicable to HF research with the aim of streamlining the clinical trial process and decreasing the time and cost required to bring safe, effective, treatments to patients who need them. The paper is based on discussions among clinical trialists, industry representatives, regulatory authorities, and patients, which took place at the Cardiovascular Clinical Trialists Workshop in Washington, DC, on 8 December 2019 (https://www.globalcvctforum.com/2019 (14 September 2020)).
Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know
Upasana Tayal, James S Ware, Neal K Lakdawala, Stephane Heymans, Sanjay K Prasad
doi : 10.1093/eurheartj/ehab286
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2384–2396
There is increasing understanding of the genetic basis to dilated cardiomyopathy and in this review, we offer a practical primer for the practising clinician. We aim to help all clinicians involved in the care of patients with dilated cardiomyopathy to understand the clinical relevance of the genetic basis of dilated cardiomyopathy, introduce key genetic concepts, explain which patients and families may benefit from genetic testing, which genetic tests are commonly performed, how to interpret genetic results, and the clinical applications of results. We conclude by reviewing areas for future research in this dynamic field.
The multiple options of left atrial and ventricular venting during veno-arterial extra-corporeal membrane oxygenation: practical considerations
Enzo Lüsebrink, Steffen Massberg, Martin Orban
doi : 10.1093/eurheartj/ehaa1073
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Pages 2399–2400
Left ventricular non-compaction
Venkatakrishnan Ramakumar, Vibhav Sharma, Sundeep Mishra
doi : 10.1093/eurheartj/ehab099
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Page 2398
Lethal enterovirus myocarditis in a patient with granulomatosis with polyangiitis following rituximab and high-dose steroid therapy
Karin Klingel, Peter P?ml, Johannes Strunk, Martin-Lorenz Werthmann
doi : 10.1093/eurheartj/ehab269
European Heart Journal, Volume 42, Issue 24, 21 June 2021, Page 2401
